

Chapter 2

Adipose Stem Cells and Adipogenesis

Ursula A. White and Yourka D. Tchoukalova

Keywords Adipose stem cells • White adipose tissue • Adipocytes • Adipogenesis • Obesity • Adipose tissue depots • Transcriptional control of adipocyte development

Key Points

- Although most development occurs during prenatal and early postnatal life, white adipose tissue retains the ability to expand during adult life, especially to accommodate energy surplus. Adipose tissue expansion occurs by increase of existing adipocytes' size or by recruiting new fat cells. Evidence in human subjects suggests that obesity complications result from the inability of subcutaneous adipose tissue to expand and safely store lipids, which leads to ectopic deposition in other tissues and insulin resistance due to lipotoxicity. This impaired expandability is due to the limited ability of adipose tissue progenitor cells to supply new adipocytes through their differentiation into specialized cells (adipogenesis). Therefore, understanding the mechanisms regulating adipogenesis is important not only for gaining insight into the pathogenesis of metabolic diseases but also for identifying targets for pharmacological interventions.
- Mature adipocytes develop from committed preadipocytes through a process termed terminal differentiation. The molecular regulation of white adipocyte terminal differentiation is extensively characterized via utilization of cell lines. However, the preceding process involves commitment of adipose stem cells (ASCs) to the adipocyte lineage with the loss of capacity to differentiate into other cell types, known as determination. Little information is known about the mechanisms that regulate the adipocyte commitment phase. Current investigations are focused on elucidating this poorly characterized step in adipocyte development. This chapter summarizes recent findings regarding the role of ASCs in adipogenesis.
- Convincing evidence for distinct depot-dependent populations of ASC pools is emerging, as adipocyte progenitors may contribute to regional variation in white adipose tissue function and development. Thus, a summary of depot-dependent differences in the gene expression patterns and cellular dynamic properties of adipocyte progenitor cells is presented.
- Finally, new lines of evidence analyzing how obesity impacts ASC abundance and functional potential are included.

U.A. White, Ph.D. • Y.D. Tchoukalova, Ph.D. (✉)
Department of Biology of Adipose Tissue Depots, Pennington Biomedical Research Center,
6400 Perkins Road, Baton Rouge, LA 70808, USA
e-mail: yourka.tchoukalova@pbrc.edu

Abbreviations

ASCs	Adipose stem cells or adipose-derived stem cells
WAT	White adipose tissue
MSCs	Mesenchymal stem cells
SVF	Stromovascular fraction
ESCs	Embryonic stem cells
iPSC	Induced pluripotent stem cells
hMADS	Human multipotent adipose-derived stem
APCs	Adipocyte precursor cells
VAT	Visceral adipose tissue
SAT	Subcutaneous adipose tissue
Pref-1	Preadipocyte factor 1
COL6A2	Type VI collagen alpha 2 chain
FRP2/SFRP2	Frizzled-related protein 2
DIPA	Delta-interacting protein A
Zfp423	Zinc-finger protein 423
LXR α	Liver X receptor alpha
BMP(s)	Bone morphogenetic proteins
IGF-1	Insulin-like growth factor-1
FGF	Fibroblast growth factors
Lox	Lysyl oxidase
Gpc4	Glypican 4
Nr2f1	Nuclear receptor subfamily 2 group F member
Shox2	Short stature homeobox 2
En1	Engrailed 1
PBX1	Pre-B-cell leukemia transcription factor

Introduction

Adipocytes are highly specialized cells that form and store fat in adipose tissue and play a major role in energy homeostasis in vertebrate organisms. Obesity results from an energy surplus and is characterized by an increased storage of lipid and expansion of adipose tissue. Obesity modifies the endocrine and metabolic functions of adipocytes and is a risk factor for many other metabolic diseases, including type II diabetes, cardiovascular ischemic disease, atherosclerosis, and hypertension.

Although most development occurs during prenatal and early postnatal life (reviewed in [1]), white adipose tissue (WAT) retains the ability to expand during adult life, especially to accommodate energy surplus. Adipose tissue expansion occurs in two ways—by increase of existing adipocytes' size (hypertrophy) or by recruiting new fat cells (hyperplasia). Accumulating evidence in human subjects suggests that obesity complications result from the inability of subcutaneous adipose tissue to expand and safely store lipids, which leads to ectopic deposition in other tissues and insulin resistance due to lipotoxicity. This impaired expandability is due to the limited ability of adipose tissue progenitor cells to supply new adipocytes through their differentiation into specialized cells (adipogenesis) (reviewed in [2]) [3–6]. Hence, in order to support expansion of adipose tissue mass and to maintain adipose dynamics in adults, proliferative adipocyte precursor cells (APCs) must exist to accommodate metabolic demands. Furthermore, recent studies by Spalding et al. suggest that approximately 10 % of the body's adipocytes

are regenerated each year [7]. In addition, adipocyte number can increase during the development of obesity, despite a higher rate of apoptosis [8]. Therefore, an adipocyte precursor pool is thought to remain present in adipose tissue during adult life and contribute to the renewal of new, mature adipocytes. Very few data is available regarding the nature of APCs, including commitment to the preadipocyte, as well as the processes that control adipose conversion and formation of new adipocytes in human adult adipose tissue. Understanding the origin of adipocyte precursors, as well as adipocyte differentiation, is relevant not only for gaining insight into the pathogenesis of metabolic diseases but also for identifying proteins or pathways which might be appropriate targets for pharmacological interventions. It is important to note that the developmental origin of white and brown fat is distinct, and different precursor cells are involved in the generation of these different types of adipose tissue (reviewed in [9]) [10].

The initial phase of white adipocyte differentiation is known as determination and involves the commitment of mesenchymal stem cells (MSCs) to the adipocyte lineage [11]. Determination results in the conversion of MSCs to preadipocytes, with the loss of capacity to differentiate into other cell types. Current investigations are focused on elucidating this poorly characterized step in adipocyte development. The second phase of adipogenesis is terminal differentiation, whereby preadipocytes assume the characteristics of mature adipocytes. Conversely, the molecular regulation of white adipocyte terminal differentiation is more extensively characterized via utilization of cell lines.

In recent years, much effort has been given to identify, isolate, and analyze APCs. Several laboratories have identified a source of multipotent stem cells, known as adipose-derived stem cells (ASCs) that are capable of proliferation and differentiation into multiple lineages *in vitro* and *in vivo*, including adipocytes, osteoblasts, chondrocytes, and myocytes [12–20]. ASCs have been defined by a variety of other terms, including the following: processed lipoaspirate cells, adipose-derived stromal cells, adipose-derived mesenchymal progenitor cells, and stromovascular fraction (SVF) (reviewed in [21]). Isolated ASCs have been shown to confer multiple lineages; however, the ability of ASCs to form tissues *in vivo* under specific experimental conditions may not accurately reflect their multilineage capacity in physiological contexts. Hence, it remains to be determined whether native ASCs within WAT behave in the same manner. In this chapter, we will review recent findings highlighting the role of ASCs in adipogenesis with a focus on the adipocyte commitment phase. We will also evaluate the influence of regional adipose tissue distribution as well as obesity on ASC biology.

Research Tools to Study Adipogenesis

Interestingly, the majority of studies that have identified molecular pathways and transcriptional regulators involved in adipogenesis have been performed *in vitro* using well-characterized cellular models. These studies have been primarily conducted in the 3T3-L1 or 3T3-F442A murine preadipocyte cell lines that were originally generated in the laboratory of Dr. Howard Green at Harvard University [22, 23]. In the last 37 years, these cell lines have been used by thousands of investigators worldwide. These clonal cell lines possess the properties of adipocytes *in vivo* and are homogeneous in regards to cellular population and differentiation stage, which allows a uniform response to treatments. In addition, these cells can be passaged indefinitely. The preadipocyte cell lines developed by Dr. Green have been extremely useful model systems for adipocyte biologists, and the data obtained in these cells have been validated from less mechanistic *in vivo* studies in the last decade.

Though cell culture systems have been useful to investigate adipogenesis, there are limitations of *in vitro* cellular models. *In vivo* adipocytes do not exist as a monolayer of identical cells, but in a complex environment comprised of various other cell types and influential factors within an extracellular matrix. In addition, cell lines are already committed to the preadipocyte lineage, and therefore cannot be

utilized to examine preadipocyte commitment phases. Despite substantial progress in defining adipogenic transcriptional control mechanisms, there is little *in vivo* information regarding the processes that regulate the commitment of adipose tissue-derived stem cells to a defined adipocyte lineage or the development of adipocyte progenitors into adipocytes.

An alternative approach for analyzing adipocyte commitment is the use of embryonic stem cells (ESCs) derived from the inner cell mass of mouse blastocysts. ESCs are able to differentiate into various lineages; therefore, pretreatment with retinoic acid (RA) is necessary to facilitate commitment to the adipose lineage and subsequent differentiation into adipocytes with adipogenic hormones [24]. Though ethical issues in extracting ESCs from human subjects limit their use in a clinical context, many laboratories utilize rodent ESCs to acquire valuable information regarding adipocyte development. Conversely, novel ESC-like pluripotent cells, termed induced pluripotent stem cells (iPSC), were generated from human skin fibroblasts by introducing various transcription factors (Oct3/4, Sox2, Klf4, and c-Myc) [25–27]. Hence, the generation of iPSC offers a method of analyzing human precursor cells by overcoming the immunological and ethical problems associated with ESCs. Although iPSC were shown to undergo adipogenesis [28], these induced cells are not a homogeneous adipocyte precursor population and have low adipogenic potential compared to other human adipose tissue-derived cells.

Additional stem cell lines have yielded valuable information regarding adipocyte development. The multipotent cell line of C3H/10T1/2 fibroblasts represents another good model to study adipocyte commitment, as *in vitro* exposure to 5-azacytidine, an inhibitor of methyltransferases, followed by adipogenic, chondrogenic, or myogenic stimuli can initiate differentiation into the respective mesenchymal cell type [29, 30]. Likewise, human multipotent adipose-derived stem (hMADS) cells are also a unique cell model to analyze adipocyte development [31], as they are isolated from the adipose tissue of young donors. These hMADS cells exhibit the characteristics of MSCs, i.e., the capacity to self-renew, as cells can be expanded *in vitro* for more than 160 population doublings (i.e., around 30 passages) while maintaining a normal diploid karyotype and multipotency at clonal level. These cells also have the capacity to differentiate into cells of the adipogenic, osteogenic, and myogenic lineages [19].

Primary preadipocytes, isolated and cultured from the SVF of adult adipose tissue explants, are able to proliferate and differentiate into mature adipocytes under appropriate adipogenic stimuli and can also be utilized for *in vitro* analysis of adipocyte development (reviewed in [32]) [33–36]. However, primary culture has disadvantages in that large amounts of adipose tissue are required, as preadipocytes comprise a small percentage of total fat tissue. Furthermore, preadipocytes are difficult to isolate from other fibroblast-like cells, and once isolated, have a limited life-span. Primary cultures also undergo a dramatic decrease in their ability to differentiate, and replicative senescence occurs with repeated subculturing. Nevertheless, primary preadipocyte cultures may more accurately represent adipose tissue function *in vivo*, as these cells are derived from an environment where various cell types and the natural milieu may influence differentiation and responsiveness. For instance, the proliferation and differentiation of both human and rodent primary preadipocytes have been shown to be influenced by the anatomic location of the depot as well as aging and gender [5, 33, 37–46].

Interestingly, several studies have demonstrated that mature adipocytes derived from adipose tissue have the ability to dedifferentiate *in vitro* into fibroblast-like stem cells by utilizing the ceiling culture technique [47–52]. Though dedifferentiated fat cells are a homogeneous mixture of adipocyte progenitors, it is unknown whether the level of dedifferentiation reaches that of native adipocyte progenitors or stem cells. Nevertheless, dedifferentiated fat cells can proliferate and differentiate into mature adipocytes both *in vitro* and *in vivo* [52] and, hence, can be a useful tool for studying *in vivo* adipogenesis.

The Characterization of Adipose Stem Cells

Characterization of ASCs has yielded conflicting findings, partially due to differences in isolation and culture techniques [53]. Notably, one cannot distinguish between ASCs and committed preadipocytes in culture, due to the lack of bona fide markers. Therefore, one of the greatest issues limiting the progression of ASC clinical research is the lack of consistency among research groups in defining the term “ASC.” Likewise, many laboratories use the crude SVF, which is a mixture of all cells comprising the adipose tissue, such as endothelial cells, smooth muscle cells, various immune cell types (neutrophils, mast cells, and macrophages), and adipocyte progenitor cells. Yet, researchers classify these cells as ASCs. Conversely, others utilize the expanded and passaged adherent cell population derived from the SVF, which are enriched with adipocyte progenitor cells. Hence, the crude SVF cells, genuine ASCs, and committed preadipocytes may all exhibit different features and properties. Overall, a standardized ASC characterization will allow direct comparison of scientific results and clarify the potential clinical applications of ASCs.

Flow cytometry has been the most valuable in recent progress toward characterizing the cell populations of ASCs, and several laboratories have proposed cell surface marker expression profiles for ASCs (reviewed in [54]). More recently, cell surface markers have been identified to define adipocyte progenitor cell populations of ASCs that differentiate into adipocytes and form functional adipose tissue. Based on numerous observations, the surface marker expression pattern of adipocyte progenitor cells is believed to be Lin[−], Sca-1⁺, CD34⁺, CD31[−], CD45[−], CD105[−], CD24⁺, CD29⁺ [55–59]. Notably, CD34⁺ cells are distinct with regard to adipogenic progenitors and distinguish between different subgroups of ASCs, as they are more adipogenic than CD34[−] populations in vitro [55, 57, 59, 60]. One compelling study revealed that exclusion of CD34⁺ cells in human skeletal muscle studies inhibits ectopic adipose tissue formation in vitro and in vivo [61]. Recent work by Maumus et al. supports previous evidence that native ASCs are contained in the CD34⁺ cell population of WAT [62]. Additional markers have offered valuable information regarding preadipocyte commitment. Preadipocyte factor 1 (Pref-1) is an accepted marker of preadipocytes [63] but is also expressed in other cell types. Other preadipocyte markers include the type VI collagen alpha 2 chain (COL6A2) [64] and a secretory protein FRP2/SFRP2 [65]. All of these factors are highly expressed in undifferentiated preadipocytes and reduced in mature adipocytes; however, none are adipose tissue specific. Overall, the use of inconsistent surface markers for different experiments has made it difficult to compare results and draw definitive conclusions. Notably, some analyses of ASCs vary in the detection of CD133, a marker that is characteristic of stemness [3, 18]. Based on these data, it is suggested that identifying ASCs by the expression of a widely used set of cell surface markers will likely not be sufficient and proposed that identity should be established by physiological properties and function [66]. Therefore, ASCs have been characterized through functional assays, in which isolated cellular fractions are tested for proliferation and differentiation capacity in both in vitro cell culture and in vivo transplantation experiments. The limitation of these methods is that ASCs are removed from their natural cellular environment, which may alter their normal function.

Comprehensive gene expression studies have been carried out by various groups and reveal distinct genetic profiles for ASCs compared to other stem cell populations of different origins. Interestingly, ASCs and bone marrow-derived MSCs share many gene expression patterns and may be closely related [18, 67]. Likewise, a comprehensive proteomic analyses of the ASC secretome determined that cytokine secretory profiles are similar to that of bone marrow-derived MSCs (reviewed in [68]). Epigenomic analyses of ASCs have been also performed during the last decade and have revealed that DNA methylation and posttranslational histone modifications greatly influence gene activity (reviewed in [69–72]). Epigenetic studies of human ASCs have located a large number of transcriptionally repressed hypermethylated gene promoters, primarily of genes encoding proteins involved in signaling and developmental functions pertaining to early fetal development.

However, promoter methylation changes after adipogenesis of ASCs are specific but did not correlate with their differentiation, suggesting that the adipose-tissue specific combinatorial changes of the DNA methylation and the histone code may contribute to the transcriptional regulation of genes involved in adipogenesis. Notably, many of these hypermethylated promoters are also found in stem cells from other tissues, supporting the view of common ontogeny of MSCs.

An interesting novel approach that characterizes the electrophysiological properties of the ion channels of ASC using a whole-cell voltage clamp technique has been recently established [73–76]. These studies detect high levels of mRNAs of various ion channel subunits and also identify Ca^{2+} -activated K^+ outward currents, characterized by rapid or slow activation, with an insignificant contribution from inward currents. Importantly, they demonstrate that these functional ion channels may contribute to the regulation of proliferation and differentiation. In addition, the depot-dependent differences in the membrane potential and electrophysiological properties of ASCs reflect their adipogenic potential and could thus be used as markers of adipogenesis [74]. Additional studies have shown that the activity of the large conductance K^+ channels in smooth muscle cells is modulated by phosphorylation via specific receptor-mediated signaling cascades [77], suggesting the possibility that the ion channels in ASCs could be effectors of receptor-dependent pathways of adipogenesis regulatory factors. The molecular mechanisms that underlie the link between ion conductance and ASCs require further analysis. Lastly, it is also hypothesized that ASC mechanical biomarkers can be used to identify cell types as well as predict tissue-specific lineage differentiation potential for ASCs [78].

Development of ASCs into the Adipocyte Lineage

Though controversy surrounds the developmental origin of ASCs and their association with adipocyte development, numerous studies have shown that ASCs can undergo adipogenesis in vitro and form adipose tissue in vivo, following culturing and adipogenic induction in vitro [79–81]. Novel data by both Rodeheffer et al. and Tang et al. highlight the detection and origin of white ASCs. Using cell surface markers (flow cytometry) or lineage tracing, they identified and isolated a population of murine undifferentiated APCs resident within the adipose tissue SVF cells that is capable of in vitro adipogenesis as well as proliferating and differentiating into a functional adipose tissue depot in vivo in rodents [57, 58]. This was evidence that WAT contains adipocyte precursors.

Significant advances toward understanding the regulatory processes involved in adipogenesis have largely been made by the identification of transcription factors and pathways that contribute to the adipogenic process (reviewed in [9]). The adipogenic cascade centers on the expression and activation of $\text{PPAR}\gamma$, the master transcriptional regulator of adipogenesis. Three members of the C/EBP family (α , β , δ) also play important roles in differentiation and act in a feedback loop to regulate $\text{PPAR}\gamma$ expression. In addition to these central players, Krox20 (also known as early growth response gene 2, or Egr2), several members of the KLF family, STAT5, and SREBP-1c have been reported to promote adipogenesis, while GATA2/3, ETO/MTG8, CHOP10, GILZ, Delta-interacting protein A (DIPA), KLF2, FoxO1, and TCF/LEF are inhibitory (reviewed in [82]). The expression and activity of these transcription factors play an important role in modulating a variety of target genes that are important in conferring lipid accumulation, insulin sensitivity, and endocrine properties in mature adipocytes.

Though poorly understood, novel transcriptional regulators and factors that modulate WAT pre-adipocyte commitment are being identified. Studies by the Spiegelman laboratory have identified two transcription factors, $\text{PPAR}\gamma$ and zinc-finger protein 423 (Zfp423), that are expressed in adipogenic fibroblast cells, as opposed to nonadipogenic cells [83]. This evidence supports previous studies that establish $\text{PPAR}\gamma$ as a marker of preadipocytes [58]. Conversely, this report identifies Zfp423 as a novel transcriptional regulator of preadipocyte commitment, as exogenous expression of Zfp423 in nonadipogenic cells is sufficient to increase $\text{PPAR}\gamma$ expression and their adipogenic potential and knockout or knockdown of this transcription factor inhibits in vitro adipogenesis [83].

Recent work characterizes *Zfp467* as another potential transcriptional regulator of preadipocyte commitment [84]. Likewise, exogenous expression of *Zfp467* enhances the cells' adipogenic potential and upregulates PPAR γ , adiponectin, and C/EBP α , while knockdown of this transcription factor impairs adipogenesis.

Recently, a study identified a novel transcription factor *Ets2*, a member of the ETS transcription factor family, which coordinately regulates expression of genes altered during different time points of pre- and postnatal adipose tissue development in mice [85]. Experiments in differentiating 3T3-L1 preadipocytes show that *Ets2* stimulates mitotic clonal expansion during the adipocyte commitment phase [85]. Interestingly, another member of the ETS domain-containing transcription factors from the PEA3 subgroup, ETV4, has been reported as one of the mediators of the adipogenic effect of a small molecule phenamil, which acts as an upstream inducer of the PPAR γ expression [86].

Additional candidates that could be involved in adipocyte commitment have been identified using a comprehensive transcriptional analysis of in vitro differentiating hMADs [87]. A computational analysis of transcription binding sites in their promoters identifies a potential role for regulation by the nuclear hormone receptors, including liver X receptor alpha (LXR α), PPAR γ , and COUP-TF1, an orphan nuclear receptor acting predominantly as a transcriptional repressor. In addition, several laboratories have investigated other potential transcriptional and paracrine regulators of preadipocyte commitment utilizing gene expression profiling of both adipogenic and nonadipogenic cells [58, 83], such as *Gsc*, *Twist2*, *Mmp3*, *Egfr*, *Fgf10*, *Efemp1*, *Lgals3*, *Igfbp4*, and *Lpl*.

Multiple signaling factors have been shown to influence the development of ASCs into adipocytes by an autocrine and/or paracrine mechanism, such as bone morphogenetic proteins (BMPs) [88], transforming growth factor β (TGF β) (reviewed in [89]), insulin-like growth factor-1 (IGF-1) (reviewed in [90]), fibroblast growth factors (FGF) 1 and 2 [91, 92], and activin [93]. Various studies have also revealed negative regulators of adipocyte development, such as Hedgehog signaling [94] and WNT signaling, whose suppression in both in vitro and in vivo adipocyte development is essential for adipogenesis (reviewed in [95]). Additional intracellular signaling pathways have also been implicated in the adipogenic cascade, whose functions are continuously revealed (reviewed in [96]). Limited studies have shown that cell shape as well as extracellular matrix components may also influence adipocyte lineage commitment (reviewed in [97, 98]).

Members of the TGF- β superfamily, notably BMP-2 and BMP-4, have been shown to stimulate commitment toward the white adipocyte lineage [88, 99–101]. Specifically, BMP-4 upregulates PPAR γ expression and enhances adipogenesis both in vitro and in vivo after implantation into mice [101]. Moreover, BMPs have been shown to exert their proadipogenic effects through the intracellular proteins Smads, which may also be important for preadipocyte commitment. Notably, both *Zfp423* and *Schnurri-2* are BMP-dependent transcriptional coactivators of Smad proteins [102], which confer their proadipogenic effects [83, 103]. Likewise, expression of BMP-4, BMP-4 receptors, and Smads is elevated in a cell line of MSCs that have increased adipogenic potential [100]. Lysyl oxidase (Lox) is another BMP-dependent transcriptional target of Smad 1/4 that is important for preadipocyte commitment; as knockdown of Lox impairs the commitment of MSCs to the adipocyte lineage and inhibits the adipogenesis of murine fibroblasts [88]. Collectively, these studies highlight the importance of BMP-2/4, Smads 1/4/5/8, and Lox as positive regulators of white preadipocyte commitment in rodents.

In recent years, activins, which are secreted proteins of the TGF β family, have emerged as regulators of the ASC pool as well as the function of mature adipocytes (reviewed in [104]). They represent dimers composed of various combinations of four inhibin β subunits, β A, β B, β C, and β E. Adipocytes and ASCs express homodimers of β A and β B, named activin A and activin B respectively, as well as the heterodimer β A and β B named activin AB. Activin A is highly expressed in human ASCs and displays proliferative and antiadipogenic effects via the Smad 2 pathway. In contrast, activins B and AB are highly expressed in mature adipocytes, particularly in obesity, and contribute to their insulin resistant and inflammatory state. The activity of activins is controlled by a binding protein follistatin, which is decreased in obesity. Thus, the ratio of the follistatin/activin complex appears to be an important regulator of the ASC pool and adipocyte function that requires further investigation.

Studies have also identified FGFs as positive regulators of preadipocyte commitment. Exposure of cultured rat MSCs or human ASCs to FGF2 leads to increased expression of PPAR γ and enhanced adipogenesis [105, 106]. Likewise, exogenous FGF2 confers *in vivo* WAT formation via isolated human SVF cells [107]. FGF-10 is expressed primarily in WAT preadipocytes and facilitates increased proliferation, but does not affect their differentiation [108]. FGF-1 has been shown to enhance the adipogenesis of human preadipocytes [109].

The Origin of Adipocyte Progenitors

Adipocytes are generally thought to arise from mesodermal stem cells residing in the adipose tissue stroma; however, previous work has postulated that adipocyte precursors may exist in the adipose vasculature, embedded in the walls of blood vessels in WAT [58, 59]. Additional studies have also shown that preadipocytes may derive from mural cell origin, as adipocytes and pericytes may share a common origin [17, 55, 57, 110, 111]. Committed preadipocytes have been shown to express pericyte markers, notably SMA, NG2, and PDGFRB [58], which is characteristic of mural cells and required for their formation (reviewed in [112]). Hence, committed preadipocytes may constitute a subset of mural cells (i.e., pericytes) in WAT. These findings support earlier studies indicating that angiogenesis and adipogenesis are tightly correlated (reviewed in [113]) and [114, 115]. Consequently, other evidence suggests that proliferating progenitor cells are located in the stromal fraction of human adipose tissue [62]. Interestingly, recent analysis of intact human WAT revealed that ASCs were found scattered in the adipose tissue stroma, and these ASCs did not express pericytic markers *in situ*, as previously reported [62]. Though it has been widely accepted that adipocytes arise entirely from the mesoderm, evidence has also shown that neuroepithelial cells derived from mouse ESCs can undergo adipogenesis *in vitro* [116, 117]. Hence, the neuroectoderm could be a source of adipocytes. Though Billon et al. were able to show that adipocytes *in vivo* arise from the neural crest, only a subset of adipocytes in specific depots, notably the cephalic region, may be of neuroectoderm origin.

Interestingly, evidence suggests that nonadipose tissue-resident progenitors are able to migrate to adipose tissue, undergo adipogenesis, and contribute to the white adipocyte pool. Hong et al. demonstrated that circulating fibrocytes (peripheral blood mononuclear cells) can undergo adipogenesis *in vitro* as well as form adipocytes *in vivo* after implantation into SCID mice [118]. It was also reported by several studies in rodents that adipocytes may derive from circulating bone marrow cells [119–121]. However, an additional study found the opposite and suggests that bone marrow-derived cells do not differentiate into adipocytes or contribute to adipose tissue development [122]. Additional bone marrow reconstitution studies demonstrate that bone marrow progenitor-derived adipocytes and adipocyte progenitors do indeed derive from hematopoietic cells via the myeloid lineage [123]. Yet, the adipocytes developed from these progenitors were different from traditional white adipocytes, in that they had increased expression of inflammatory cytokines and decreased expression of leptin and other genes involved in mitochondrial biogenesis and lipid oxidation, supporting previous conclusions that contribution of bone marrow-derived progenitors to functional WAT may be negligible [120, 122]. Of consideration, these bone marrow progenitor-derived adipocytes accumulated more in VAT depots compared to SAT and were more plentiful in women compared to men; therefore, accumulation of adipocytes from bone marrow origin may contribute to adipose tissue depot heterogeneity.

Overall, evidence to support the origin of adipocytes from areas outside the mesoderm is controversial, and whether the adipocyte precursor population is resident within the adipose tissue and/or originates from the recruitment of circulating progenitor cells remains to be determined. Lack of specific cell surface markers to identify human adipocyte origins precludes the accurate isolation of human APCs and analysis of the adipogenic cascade. Though resident pools of APCs have been identified in rodents, these cells are not fully identified in humans; hence, the exact nature of human preadipocytes still remains unclear.

Effects of Obesity on ASC Pool

Due to the inability to analyze the varying degrees of cell turnover in humans, few data are available concerning human adipocyte precursor renewal within adipose tissue; although this process is essential to maintain a preadipocyte pool to be available during WAT expansion. The development, availability, and response of the adipocyte progenitor pool define an individual's capacity for adipose tissue expandability. Hence, characterizing factors that regulate the size and differentiation of adipocyte progenitor pools may denote novel therapeutic strategies to control the deposition of lipid due to excess energy surplus. Likewise, new lines of evidence are analyzing how obesity impacts ASC biology. Detrimental consequences of adipose tissue remodeling, resulting from adipocyte hypertrophy, hypoxia, and local inflammation [124], include enhanced proliferation of preadipocytes [125, 126], with concurrent inhibition of preadipocyte differentiation [127–130] and increased preadipocyte apoptosis [131]. Therefore, phases of adipocyte hyperplasia would be achieved with increased requirements for proliferation coupled with successive less efficient adipogenesis. Frequent cycling will thus promote replicative senescence of adipocyte progenitor cells with gradual impairment of adipocyte function and viability. Overall, obesity would promote accelerated exhaustion of the adipocyte progenitor pool, decreased capacity for preadipocyte self-renewal, and extensive adipose tissue remodeling, all leading to impaired expandability of subcutaneous adipose tissue, ectopic lipid accumulation, and obesity-related metabolic perturbations (insulin resistance). Isakson et al. demonstrated impaired differentiation of preadipocytes from the stromal fraction of subcutaneous abdominal adipose tissue from obese versus lean individuals [3]. Early studies using thymidine incorporation into fat cell DNA reported increased preadipocyte proliferation in high fat diet-fed rats [132]. More recent reports demonstrate that human subcutaneous abdominal adipose tissue has increased proliferation of adipocyte precursors in increasing obese conditions [126]. Yet, other studies indicate that preadipocyte numbers in the SVF were lower in obese women as compared to lean [4]. However, the aforementioned observations could be attributed to greater recruitment of preadipocytes to adipogenesis or greater preadipocyte apoptosis. Recent evidence suggests that adipocyte precursor/preadipocyte number may depend on the degree of obesity; as humans with morbid obesity, with corresponding excessive AT development, had decreased ASCs (heterogeneous fraction), compared to individuals with moderate obesity [62]. This decrease was accompanied by smaller mean adipocyte diameter and a marked increase in the expression of adipogenic markers, suggesting increased proliferation of preadipocytes and/or increased differentiation of new preadipocytes. Indeed, recent compelling data reported decreased replicative potential, premature cellular senescence, and loss of the multilineage differentiation potential of omental ASCs from patients with morbid obesity compared to lean individuals [133]. In addition, recent findings have also shown that chronic thiazolidinedione treatment decreases the adipogenic potential of ASCs, exhausting the pool of committed preadipocytes in WAT [134].

Depot Differences of ASC Pool

It is well documented that differences in regional fat distribution affect metabolic parameters in humans, presumably due to intrinsic differences in function of the adipose tissue [135–139]. The two types of WAT, visceral (VAT) and subcutaneous (SAT), are defined by location, and the mechanisms and developmental signals that account for each depot's unique characteristics are steadily emerging. Studies have revealed that subcutaneous upper body depots and visceral depots both correlate with an increased susceptibility for metabolic perturbations [140, 141], while lower-body fat is protective [138, 142–144] (reviewed in [145]). In addition, evidence suggests that VAT expands predominantly by adipocyte hypertrophy, while SAT by adipocyte hyperplasia with nutritional overload [146]. While numerous studies have investigated regional differences in adipose tissue metabolism [147–150],

few have examined depot-specific differences in adipocyte progenitor development. Subsequently, convincing evidence for distinct depot-dependent populations of ASC pools is emerging, as adipocyte progenitors may contribute to regional variation in WAT function and development. Early studies from the Kirkland laboratory revealed that abdominal subcutaneous preadipocytes derived from adipose stromal cells accumulated more lipids and had higher differentiation capacity and levels of adipocyte markers compared to visceral preadipocytes from obese subjects [151]. Studies performed in primary cultures also showed that the proliferation and differentiation capacity of ASCs from subcutaneous precursor cells was higher than in omental cells in obese individuals [148]. Flow cytometric analysis supported previous data by validating that the number of CD34⁺/CD31⁻ SVF cells from gluteal SAT positively correlated with increasing BMI of overweight individuals [152]. Additional lines of evidence indicate that SAT adipocyte precursors in rodents are more abundant and have increased proliferation as compared to VAT adipocyte progenitors in response to high-fat diet [146]. Notably, recent studies by Macotela et al. that highlight the intrinsic differences of VAT versus SAT preadipocyte pools in rodents reveal that visceral APCs display less differentiation capacity, and VAT has a decreased percentage of APCs following high-fat diet, with subsequent increase in other SVF cells (i.e., macrophages). They also demonstrate that visceral APCs highly express antiadipogenic factors, as opposed to subcutaneous APCs, which show higher expression of proadipogenic genes [153]. Overall, the reduced differentiation capacity of visceral preadipocytes may account for the increased hypertrophy of existent adipocytes and the metabolic abnormalities associated with visceral adipose tissue. Hence, depot-specific differences in adipocyte progenitor abundance and proliferation influence whether a fat depot expands by hypertrophy or hyperplasia, and thus may have important implications on the development of metabolic disease.

Though the aforementioned data collectively indicate that subcutaneous depots contain a greater number of functional adipose progenitors as compared to visceral depots, these findings are controversial. Other investigations indicate that preadipocytes from upper body (abdominal) SAT of obese women differentiate less readily and are more susceptible to apoptosis as compared to the lower body (femoral) depot [4]. These results support previous reports in primary cultures showing that subcutaneous abdominal preadipocyte differentiation inversely correlates with increased obesity and central adiposity [154]. Thus, the SVF of subcutaneous abdominal fat tissue from centrally obese individuals might contain more preadipocytes with impaired differentiation potential than tissue from lean individuals. This provides evidence that abdominal VAT and abdominal SAT may share similar properties, as previously shown [74]. Overall, these studies are complicated due to the lack of distinct markers of ASCs and preadipocytes and the complexity in defining precisely where in the commitment and differentiation phase a given cell may be.

Transcriptional profiling has revealed limited yet valuable information about depot-specific differences in adipose tissue, as morphological and functional differences in developmental gene expression have been reported in rodents and humans [155–158]. Adipocytes from VAT express higher levels of *HoxA5*, *HoxA4*, *HoxC8*, *Glypican 4* (*Gpc4*), *Thbd*, and *Nr2f1* (*nuclear receptor subfamily 2 group F member 1*), whereas subcutaneous WAT has higher levels of *HoxA10*, *HoxC9*, *Tbx15*, *Shox2* (*Short stature homeobox 2*), *En1* (*Engrailed 1*), and *Sfpr2*, and most of these differences are observed in rodents and humans. Notably, depot-specific variations in gene expression were also observed in preadipocytes [147, 157]. In addition, select developmental genes, *Tbx15*, *Glyp4*, and *HoxA5*, demonstrate changes in expression that correlate with levels of obesity (body mass index) and fat distribution (waist-to-hip ratio) [157]. More extensive gene expression analyses reveal that additional genes that regulate early development, such as homeobox family members and pregnancy-associated factors, are distinct between fat cell progenitors of both rodent and human adipose tissue depots [147, 159, 160]. The observed differences in gene expression appear to be intrinsic and persist through in vitro culture and differentiation; hence, the microenvironment does not appear to be an influence. Furthermore, the results from the aforementioned experiments by Tchoukalova et al. highlighting the differences in lipid

accumulation and differentiation capacity of SAT versus VAT preadipocytes [151] were associated with distinct patterns of gene expression and conserved over multiple cell generations [158]. Collectively, these data suggest that WAT depots originate from different precursor cells, whose function is presumably controlled by genes involved in development and pattern specification. Moreover, pre-B-cell leukemia transcription factor (PBX1), a family member of the homeodomain transcription factors, has been shown to be induced after commitment of mouse ESCs to the adipocyte lineage following treatment with RA [161]. A siRNA-mediated silencing of PBX1 expression in hMADs shows that PBX1 may play a role in human adipogenesis by maintaining the proliferation of ASCs and prevention of their commitment to adipocyte lineage [161]. Although the expression of PBX1 in different depots has not yet been explored, these data strongly suggest that the depot-specific differences in preadipocyte pools are established during development. Thus, the apparent differences in adipose tissue distribution in normal and obese individuals may be derived from distinct precursors in the different WAT depots.

Sex steroids are endogenous modulators of adipose tissue development, function, and distribution of SAT versus VAT depots [162], though little is known about the cellular and molecular mechanisms of this regulation. Men often have more adipose tissue distributed in the abdominal or visceral region (“android” or “apple” phenotype), which carries a much greater risk for metabolic disorders than does adipose tissue distributed subcutaneously (reviewed in [163]). In contrast, women, have more subcutaneous adipose tissue (“gynoid” or “pear” phenotype), and this distribution is predominantly sex hormone (estrogen)-dependent [164]. Likewise, in men and menopausal women, conditions in which estrogen levels are low, visceral adiposity increases. These distinct sex differences in patterns of fat distribution often develop during puberty; hence, sex steroids may potentially regulate fat distribution through epigenetic mechanisms involving adipose progenitors. Likewise, suboptimal maternal diet predisposes to visceral obesity and metabolic syndrome [165], further supporting the role of epigenetic mechanisms in the interaction between maternal nutrition and the regional fetal development of adipose tissue.

Complexity of Characterization and Analysis of ASCs

Though much progress has been made to elucidate the mechanisms that underlie the commitment of stem cells to the adipocyte lineage, many challenges remain in elucidating the function of ASCs in adipose tissue development. SVF subpopulations that contain committed preadipocytes can only confer WAT formation *in vivo* under certain inducible conditions that are conducive to alterations in adipose tissue expansion, such as HFD or lipodystrophy [57]. Other studies provide evidence that dietary stimulus can modulate the proliferation of adipogenic progenitors [146]. Hence, the ASC natural microenvironment is significant, but cannot be fully recapitulated in the realm of culture experiments. Consequently, to date, little is known about the capacity of these adipose “stem cells” to self-renew and produce new preadipocytes in humans or undergo adipogenesis. Of note, preadipocyte replication is often analyzed as an indicator of progenitor pool activity, yet this proliferation could be either a mechanism to replenish the local pool of immature progenitor cells of the expanding adipose tissue or also an index of adipocyte progenitor cell entry into adipogenesis. Frequently, the ASCs commonly utilized for experimentation are a heterogeneous cell population with the potential to commit to other lineages; so functional differences may exist between ASCs and committed preadipocytes *in vivo*. Though recent evidence suggests that ASCs are involved in the adipogenic process [62], additional studies are necessary to elucidate the contribution of ASCs to committed preadipocytes. More knowledge about the mechanisms that regulate ASCs is necessary in order to refine and standardize laboratory techniques to isolate, characterize, and manipulate ASCs.

Importantly, analyses to understand ASCs and adipocyte origins have clinical implications, as these findings may offer insight into diseases linked to adipose tissue. The identified novel transcriptional and auto/paracrine factors that regulate adipocyte development present potential therapeutic avenues to modulate the size and management of the ASC pools as well as the adipose cell turnover rate. Likewise, this would allow the manipulation of subcutaneous adipose tissue expandability, with subsequent prevention of metabolic abnormalities associated with ectopic fat deposition and improvement of insulin sensitivity in conditions of obesity as well as lipodystrophy. Hence, continued efforts to investigate the contribution of these pathways to the regulation of adipocyte progenitor pools in different depots may lead to the prevention of metabolically unfavorable fat distribution [166].

References

1. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. *Mol Cell Endocrinol.* 2010;323(1):20–34. Epub 2009/12/23.
2. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome—an allostatic perspective. *Biochim Biophys Acta.* 2010;1801(3):338–49. Epub 2010/01/09.
3. Isakson P, Hammarstedt A, Gustafson B, Smith U. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor- α , and inflammation. *Diabetes.* 2009;58(7):1550–7. Epub 2009/04/09.
4. Tchoukalova Y, Koutsari C, Jensen M. Committed subcutaneous preadipocytes are reduced in human obesity. *Diabetologia.* 2007;50(1):151–7.
5. Hauner H, Wabitsch M, Pfeiffer EF. Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. *Horm Metab Res Suppl.* 1988;19:35–9.
6. Gregoire FM, Johnson PR, Greenwood MR. Comparison of the adipogenesis of preadipocytes derived from lean and obese Zucker rats in serum-free cultures. *Int J Obes Relat Metab Disord.* 1995;19(9):664–70. Epub 1995/09/01.
7. Spalding KL, Arner E, Westermarck PO, Bernard S, Buchholz BA, Bergmann O, et al. Dynamics of fat cell turnover in humans. *Nature.* 2008;453(7196):783–7.
8. Strissel KJ, Stancheva Z, Miyoshi H, Perfield 2nd JW, DeFuria J, Jick Z, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. *Diabetes.* 2007;56(12):2910–8. Epub 2007/09/13.
9. Lefterova MI, Lazar MA. New developments in adipogenesis. *Trends Endocrinol Metab: TEM.* 2009;20(3):107–14. Epub 2009/03/10.
10. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, et al. PRDM16 controls a brown fat/skeletal muscle switch. *Nature.* 2008;454(7207):961–7. Epub 2008/08/23.
11. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. *Nat Rev Mol Cell Biol.* 2006;7(12):885–96. Epub 2006/12/02.
12. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng.* 2001;7(2):211–28. Epub 2001/04/17.
13. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell.* 2002;13(12):4279–95. Epub 2002/12/12.
14. Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. *Biochem Biophys Res Commun.* 2002;290(2):763–9. Epub 2002/01/12.
15. Safford KM, Hicok KC, Safford SD, Halvorsen YD, Wilkison WO, Gimble JM, et al. Neurogenic differentiation of murine and human adipose-derived stromal cells. *Biochem Biophys Res Commun.* 2002;294(2):371–9. Epub 2002/06/08.
16. Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C, Boskey AL, et al. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. *Tissue Eng.* 2001;7(6):729–41. Epub 2001/12/26.
17. Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbelink M, Tamarat R, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. *Circulation.* 2004;109(5):656–63. Epub 2004/01/22.
18. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. *Stem Cells.* 2005;23(3):412–23. Epub 2005/03/08.
19. Rodriguez AM, Pisani D, Dechesne CA, Turc-Carel C, Kurzenne JY, Wdziekonski B, et al. Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. *J Exp Med.* 2005;201(9):1397–405. Epub 2005/05/04.

20. Prunet-Marcassus B, Cousin B, Caton D, Andre M, Penicaud L, Casteilla L. From heterogeneity to plasticity in adipose tissues: site-specific differences. *Exp Cell Res*. 2006;312(6):727–36. Epub 2006/01/03.
21. Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. *Cytotherapy*. 2003;5(5):362–9. Epub 2003/10/28.
22. Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. *Cell*. 1975;5(1):19–27. Epub 1975/05/01.
23. Green H, Kehinde O. Spontaneous heritable changes leading to increased adipose conversion in 3 T3 cells. *Cell*. 1976;7(1):105–13. Epub 1976/01/01.
24. Dani C, Smith AG, Dessolin S, Leroy P, Staccini L, Villageois P, et al. Differentiation of embryonic stem cells into adipocytes in vitro. *J Cell Sci*. 1997;110(Pt 11):1279–85. Epub 1997/06/01.
25. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007;131(5):861–72. Epub 2007/11/24.
26. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science*. 2007;318(5858):1917–20. Epub 2007/11/22.
27. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat Biotechnol*. 2008;26(1):101–6. Epub 2007/12/07.
28. Taura D, Noguchi M, Sone M, Hosoda K, Mori E, Okada Y, et al. Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells. *FEBS Lett*. 2009;583(6):1029–33. Epub 2009/03/03.
29. Pinney DF, Emerson Jr CP. 10 T1/2 cells: an in vitro model for molecular genetic analysis of mesodermal determination and differentiation. *Environ Health Perspect*. 1989;80:221–7. Epub 1989/03/01.
30. Taylor SM, Jones PA. Multiple new phenotypes induced in 10 T1/2 and 3 T3 cells treated with 5-azacytidine. *Cell*. 1979;17(4):771–9. Epub 1979/08/01.
31. Bezaire V, Mairal A, Ribet C, Lefort C, Girousse A, Jocken J, et al. Contribution of adipose triglyceride lipase and hormone-sensitive lipase to lipolysis in hMADS adipocytes. *J Biol Chem*. 2009;284(27):18282–91. Epub 2009/05/13.
32. Armani A, Mammi C, Marzolla V, Calanchini M, Antelmi A, Rosano GM, et al. Cellular models for understanding adipogenesis, adipose dysfunction, and obesity. *J Cell Biochem*. 2010;110(3):564–72. Epub 2010/06/01.
33. Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. *J Clin Invest*. 1989;84(5):1663–70. Epub 1989/11/01.
34. Reyne Y, Nougues J, Dulong JP. Differentiation of rabbit adipocyte precursor cells in a serum-free medium. *In Vitro Cell Dev Biol*. 1989;25(8):747–52. Epub 1989/08/01.
35. Lithauer D, Serrero G. The primary culture of mouse adipocyte precursor cells in defined medium. *Comp Biochem Physiol A Comp Physiol*. 1992;101(1):59–64. Epub 1992/01/01.
36. Kirkland JL, Hollenberg CH, Kindler S, Gillon WS. Effects of age and anatomic site on preadipocyte number in rat fat depots. *J Gerontol*. 1994;49(1):B31–5.
37. Maslowska MH, Sniderman AD, MacLean LD, Cianflone K. Regional differences in triacylglycerol synthesis in adipose tissue and in cultured preadipocytes. *J Lipid Res*. 1993;34(2):219–28. Epub 1993/02/01.
38. Tchoukalova YD, Votruba SB, Tchkonina T, Giorgadze N, Kirkland JL, Jensen MD. Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. *Proc Natl Acad Sci U S A*. 2010;107(42):18226–31. Epub 2010/10/06.
39. Djian P, Roncari AK, Hollenberg CH. Influence of anatomic site and age on the replication and differentiation of rat adipocyte precursors in culture. *J Clin Invest*. 1983;72(4):1200–8.
40. Djian P, Roncari DA, Hollenberg CH. Adipocyte precursor clones vary in capacity for differentiation. *Metabolism*. 1985;34(9):880–3. Epub 1985/09/01.
41. Wang H, Kirkland JL, Hollenberg CH. Varying capacities for replication of rat adipocyte precursor clones and adipose tissue growth. *J Clin Invest*. 1989;83(5):1741–6.
42. Kirkland JL, Hollenberg CH, Gillon WS. Age, anatomic site, and the replication and differentiation of adipocyte precursors. *Am J Physiol*. 1990;258(2 Pt 1):C206–10.
43. Sztalryd C, Faust IM. Depot-specific features of adipocyte progenitors revealed by primary cultures plated at low density. *Int J Obes*. 1990;14 Suppl 3:165–75. Epub 1990/01/01.
44. Gregoire F, Todoroff G, Hauser N, Remacle C. The stroma-vascular fraction of rat inguinal and epididymal adipose tissue and the adipoconversion of fat cell precursors in primary culture. *Biol Cell*. 1990;69(3):215–22. Epub 1990/01/01.
45. Kirkland JL, Hollenberg CH, Gillon WS. Ageing, differentiation, and gene expression in rat epididymal preadipocytes. *Biochem Cell Biol*. 1993;71(11–12):556–61. Epub 1993/11/01.
46. Carraro R, Li ZH, Johnson Jr JE, Gregerman RI. Adipocytes of old rats produce a decreased amount of differentiation factor for preadipocytes derived from adipose tissue islets. *J Gerontol*. 1992;47(6):B198–201. Epub 1992/11/11.

47. Sugihara H, Yonemitsu N, Miyabara S, Yun K. Primary cultures of unilocular fat cells: characteristics of growth in vitro and changes in differentiation properties. *Differentiation*. 1986;31(1):42–9. Epub 1986/01/01.
48. Sugihara H, Yonemitsu N, Miyabara S, Toda S. Proliferation of unilocular fat cells in the primary culture. *J Lipid Res*. 1987;28(9):1038–45. Epub 1987/09/01.
49. Yagi K, Kondo D, Okazaki Y, Kano K. A novel preadipocyte cell line established from mouse adult mature adipocytes. *Biochem Biophys Res Commun*. 2004;321(4):967–74. Epub 2004/09/11.
50. Fernyhough ME, Hausman GJ, Guan LL, Okine E, Moore SS, Dodson MV. Mature adipocytes may be a source of stem cells for tissue engineering. *Biochem Biophys Res Commun*. 2008;368(3):455–7. Epub 2008/02/07.
51. Matsumoto T, Kano K, Kondo D, Fukuda N, Iribe Y, Tanaka N, et al. Mature adipocyte-derived dedifferentiated fat cells exhibit multilineage potential. *J Cell Physiol*. 2008;215(1):210–22. Epub 2007/12/08.
52. Nobusue H, Endo T, Kano K. Establishment of a preadipocyte cell line derived from mature adipocytes of GFP transgenic mice and formation of adipose tissue. *Cell Tissue Res*. 2008;332(3):435–46. Epub 2008/04/04.
53. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. *Stem Cells*. 2006;24(2):376–85. Epub 2005/12/03.
54. Cawthorn WP, Scheller EL, MacDougald OA. Adipose tissue stem cells meet preadipocyte commitment: going back to the future. *J Lipid Res*. 2012;53(2):227–46. Epub 2011/12/06.
55. Li H, Zimmerlin L, Marra KG, Donnenberg VS, Donnenberg AD, Rubin JP. Adipogenic potential of adipose stem cell subpopulations. *Plast Reconstr Surg*. 2011;128(3):663–72. Epub 2011/05/17.
56. Joe AW, Yi L, Natarajan A, Le Grand F, So L, Wang J, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. *Nat Cell Biol*. 2010;12(2):153–63. Epub 2010/01/19.
57. Rodeheffer MS, Birsoy K, Friedman JM. Identification of white adipocyte progenitor cells in vivo. *Cell*. 2008;135(2):240–9. Epub 2008/10/07.
58. Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE, et al. White fat progenitor cells reside in the adipose vasculature. *Science*. 2008;322(5901):583–6. Epub 2008/09/20.
59. Sengenès C, Lolmede K, Zakaroff-Girard A, Busse R, Bouloumie A. Preadipocytes in the human subcutaneous adipose tissue display distinct features from the adult mesenchymal and hematopoietic stem cells. *J Cell Physiol*. 2005;205(1):114–22.
60. Festy F, Hoareau L, Bes-Houtmann S, Pequin AM, Gonthier MP, Munstun A, et al. Surface protein expression between human adipose tissue-derived stromal cells and mature adipocytes. *Histochem Cell Biol*. 2005;124(2):113–21. Epub 2005/07/21.
61. Pisani DF, Dechesne CA, Sacconi S, Delplace S, Belmonte N, Cochet O, et al. Isolation of a highly myogenic CD34-negative subset of human skeletal muscle cells free of adipogenic potential. *Stem Cells*. 2010;28(4):753–64. Epub 2010/02/06.
62. Maumus M, Peyrafitte JA, D'Angelo R, Fournier-Wirth C, Bouloumie A, Casteilla L, et al. Native human adipose stromal cells: localization, morphology and phenotype. *Int J Obes (Lond)*. 2011;35(9):1141–53. Epub 2011/01/27.
63. Villena JA, Kim KH, Sul HS. Pref-1 and ADSF/resistin: two secreted factors inhibiting adipose tissue development. *Horm Metab Res*. 2002;34(11–12):664–70. Epub 2003/03/28.
64. Ibrahimi A, Bertrand B, Bardon S, Amri EZ, Grimaldi P, Ailhaud G, et al. Cloning of alpha 2 chain of type VI collagen and expression during mouse development. *Biochem J*. 1993;289(Pt 1):141–7. Epub 1993/01/01.
65. Hu E, Zhu Y, Fredrickson T, Barnes M, Kelsell D, Beeley L, et al. Tissue restricted expression of two human Frzbs in preadipocytes and pancreas. *Biochem Biophys Res Commun*. 1998;247(2):287–93. Epub 1998/06/27.
66. Sachs PC, Francis MP, Zhao M, Brumelle J, Rao RR, Elmore LW, et al. Defining essential stem cell characteristics in adipose-derived stromal cells extracted from distinct anatomical sites. *Cell Tissue Res*. 2012;349(2):505–15. Epub 2012/05/26.
67. Jansen BJ, Gilissen C, Roelofs H, Schaap-Oziemlak A, Veltman JA, Raymakers RA, et al. Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. *Stem Cells Dev*. 2010;19(4):481–90. Epub 2009/10/01.
68. Salgado AJ, Reis RL, Sousa NJ, Gimble JM. Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. *Curr Stem Cell Res Ther*. 2010;5(2):103–10. Epub 2009/11/28.
69. Collas P. Programming differentiation potential in mesenchymal stem cells. *Epigenetics*. 2010;5(6):476–82. Epub 2010/06/25.
70. Musri MM, Gomis R, Parrizas M. Chromatin and chromatin-modifying proteins in adipogenesis. *Biochem Cell Biol*. 2007;85(4):397–410. Epub 2007/08/24.
71. Pinnick KE, Karpe F. DNA methylation of genes in adipose tissue. *Proc Nutr Soc*. 2011;70(1):57–63. Epub 2010/12/15.
72. Ge K. Epigenetic regulation of adipogenesis by histone methylation. *Biochim Biophys Acta*. 2012;1819(7):727–32. Epub 2012/01/14.
73. Bai X, Ma J, Pan Z, Song YH, Freyberg S, Yan Y, et al. Electrophysiological properties of human adipose tissue-derived stem cells. *Am J Physiol Cell Physiol*. 2007;293(5):C1539–50. Epub 2007/08/10.

74. Baglioni S, Francalanci M, Squecco R, Lombardi A, Cantini G, Angeli R, et al. Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. *FASEB J*. 2009;23(10):3494–505. Epub 2009/07/09.
75. Ramirez-Ponce MP, Mateos JC, Bellido JA. Human adipose cells have voltage-dependent potassium currents. *J Membr Biol*. 2003;196(2):129–34. Epub 2004/01/16.
76. Hu H, He ML, Tao R, Sun HY, Hu R, Zang WJ, et al. Characterization of ion channels in human preadipocytes. *J Cell Physiol*. 2009;218(2):427–35. Epub 2008/10/23.
77. Alioua A, Mahajan A, Nishimaru K, Zarei MM, Stefani E, Toro L. Coupling of c-Src to large conductance voltage- and Ca²⁺-activated K⁺ channels as a new mechanism of agonist-induced vasoconstriction. *Proc Natl Acad Sci U S A*. 2002;99(22):14560–5. Epub 2002/10/23.
78. Gonzalez-Cruz RD, Fonseca VC, Darling EM. Cellular mechanical properties reflect the differentiation potential of adipose-derived mesenchymal stem cells. *Proc Natl Acad Sci U S A*. 2012;109(24):E1523–9. Epub 2012/05/23.
79. Lee JA, Parrett BM, Conejero JA, Laser J, Chen J, Kogon AJ, et al. Biological alchemy: engineering bone and fat from fat-derived stem cells. *Ann Plast Surg*. 2003;50(6):610–7. Epub 2003/06/05.
80. Choi YS, Cha SM, Lee YY, Kwon SW, Park CJ, Kim M. Adipogenic differentiation of adipose tissue derived adult stem cells in nude mouse. *Biochem Biophys Res Commun*. 2006;345(2):631–7. Epub 2006/05/16.
81. Mauney JR, Nguyen T, Gillen K, Kirker-Head C, Gimble JM, Kaplan DL. Engineering adipose-like tissue in vitro and in vivo utilizing human bone marrow and adipose-derived mesenchymal stem cells with silk fibroin 3D scaffolds. *Biomaterials*. 2007;28(35):5280–90. Epub 2007/09/04.
82. Farmer SR. Transcriptional control of adipocyte formation. *Cell Metab*. 2006;4(4):263–73.
83. Gupta RK, Arany Z, Seale P, Mepani RJ, Ye L, Conroe HM, et al. Transcriptional control of preadipocyte determination by Zfp423. *Nature*. 2010;464(7288):619–23. Epub 2010/03/05.
84. Quach JM, Walker EC, Allan E, Solano M, Yokoyama A, Kato S, et al. Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. *J Biol Chem*. 2011;286(6):4186–98. Epub 2010/12/03.
85. Birsoy K, Berry R, Wang T, Ceyhan O, Tavazoie S, Friedman JM, et al. Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis. *Development*. 2011;138(21):4709–19. Epub 2011/10/13.
86. Park KW, Waki H, Choi SP, Park KM, Tontonoz P. The small molecule phenamil is a modulator of adipocyte differentiation and PPAR[gamma] expression. *J Lipid Res*. 2010;51(9):2775–84. Epub 2010/06/04.
87. Scheideler M, Elabd C, Zaragosi LE, Chiellini C, Hackl H, Sanchez-Cabo F, et al. Comparative transcriptomics of human multipotent stem cells during adipogenesis and osteoblastogenesis. *BMC Genomics*. 2008;9:340. Epub 2008/07/19.
88. Huang H, Song TJ, Li X, Hu L, He Q, Liu M, et al. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. *Proc Natl Acad Sci U S A*. 2009;106(31):12670–5. Epub 2009/07/22.
89. Zamani N, Brown CW. Emerging roles for the transforming growth factor- β superfamily in regulating adiposity and energy expenditure. *Endocr Rev*. 2011;32(3):387–403. Epub 2010/12/22.
90. Kawai M, Rosen CJ. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. *J Cell Biochem*. 2010;111(1):14–9. Epub 2010/05/28.
91. Widberg CH, Newell FS, Bachmann AW, Ramnoruth SN, Spelta MC, Whitehead JP, et al. Fibroblast growth factor receptor 1 is a key regulator of early adipogenic events in human preadipocytes. *Am J Physiol Endocrinol Metab*. 2009;296(1):E121–31. Epub 2008/10/23.
92. Xiao L, Sobue T, Esliger A, Kronenberg MS, Coffin JD, Doetschman T, et al. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. *Bone*. 2010;47(2):360–70. Epub 2010/06/01.
93. Zaragosi LE, Wdziekonski B, Villageois P, Keophiphath M, Maumus M, Tchkonja T, et al. Activin plays a critical role in proliferation and differentiation of human adipose progenitors. *Diabetes*. 2010;59(10):2513–21. Epub 2010/06/10.
94. Suh JM, Gao X, McKay J, McKay R, Salo Z, Graff JM. Hedgehog signaling plays a conserved role in inhibiting fat formation. *Cell Metab*. 2006;3(1):25–34. Epub 2006/01/10.
95. Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signalling. *Trends Endocrinol Metab*. 2009;20(1):16–24. Epub 2008/11/15.
96. Lowe CE, O'Rahilly S, Rochford JJ. Adipogenesis at a glance. *J Cell Sci*. 2011;124(Pt 16):2681–6. Epub 2011/08/03.
97. Feng T, Szabo E, Dziak E, Opas M. Cytoskeletal disassembly and cell rounding promotes adipogenesis from ES cells. *Stem Cell Rev*. 2010;6(1):74–85. Epub 2010/02/12.
98. Kilian KA, Bugarija B, Lahn BT, Mrksich M. Geometric cues for directing the differentiation of mesenchymal stem cells. *Proc Natl Acad Sci U S A*. 2010;107(11):4872–7. Epub 2010/03/03.
99. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3 T3 cells. *Growth Factors*. 1993;9(1):57–71. Epub 1993/01/01.

100. Bowers RR, Kim JW, Otto TC, Lane MD. Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene. *Proc Natl Acad Sci U S A*. 2006;103(35):13022–7. Epub 2006/08/19.
101. Tang QQ, Otto TC, Lane MD. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. *Proc Natl Acad Sci U S A*. 2004;101(26):9607–11.
102. Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massague J. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. *Cell*. 2000;100(2):229–40. Epub 2000/02/05.
103. Jin W, Takagi T, Kanesashi SN, Kurahashi T, Nomura T, Harada J, et al. Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins. *Dev Cell*. 2006;10(4):461–71. Epub 2006/04/04.
104. Dani C. Activins in adipogenesis and obesity. *Int J Obes (Lond)*. 2013;37(2):163–6. Epub 2012/03/01.
105. Neubauer M, Fischbach C, Bauer-Kreisel P, Lieb E, Hacker M, Tessmar J, et al. Basic fibroblast growth factor enhances PPARgamma ligand-induced adipogenesis of mesenchymal stem cells. *FEBS Lett*. 2004;577(1–2):277–83. Epub 2004/11/06.
106. Kakudo N, Shimotsuma A, Kusumoto K. Fibroblast growth factor-2 stimulates adipogenic differentiation of human adipose-derived stem cells. *Biochem Biophys Res Commun*. 2007;359(2):239–44. Epub 2007/06/05.
107. Kimura Y, Ozeki M, Inamoto T, Tabata Y. Adipose tissue engineering based on human preadipocytes combined with gelatin microspheres containing basic fibroblast growth factor. *Biomaterials*. 2003;24(14):2513–21. Epub 2003/04/16.
108. Yamasaki K, Sasaki T, Nemoto M, Eto Y, Tajima N. Differentiation-induced insulin secretion from nonendocrine cells with engineered human proinsulin cDNA. *Biochem Biophys Res Commun*. 1999;265(2):361–5. Epub 1999/11/24.
109. Hutley L, Shurety W, Newell F, McGeary R, Pelton N, Grant J, et al. Fibroblast growth factor 1: a key regulator of human adipogenesis. *Diabetes*. 2004;53(12):3097–106. Epub 2004/11/25.
110. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell*. 2008;3(3):301–13. Epub 2008/09/13.
111. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. *Circ Res*. 2008;102(1):77–85. Epub 2007/10/31.
112. Jain RK. Molecular regulation of vessel maturation. *Nat Med*. 2003;9(6):685–93. Epub 2003/06/05.
113. Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. *Microcirculation*. 1997;4(2):211–32. Epub 1997/06/01.
114. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H, et al. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. *Diabetes*. 2007;56(6):1517–26. Epub 2007/03/29.
115. Cao Y. Angiogenesis modulates adipogenesis and obesity. *J Clin Invest*. 2007;117(9):2362–8. Epub 2007/09/06.
116. Billon N, Iannarelli P, Monteiro MC, Glavieux-Pardanaud C, Richardson WD, Kessar N, et al. The generation of adipocytes by the neural crest. *Development*. 2007;134(12):2283–92. Epub 2007/05/18.
117. Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG, et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. *Cell*. 2007;129(7):1377–88. Epub 2007/07/03.
118. Hong KM, Burdick MD, Phillips RJ, Heber D, Strieter RM. Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. *FASEB J*. 2005;19(14):2029–31. Epub 2005/09/29.
119. Crossno Jr JT, Majka SM, Grazia T, Gill RG, Klemm DJ. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. *J Clin Invest*. 2006;116(12):3220–8. Epub 2006/12/05.
120. Tomiyama K, Murase N, Stolz DB, Toyokawa H, O'Donnell DR, Smith DM, et al. Characterization of transplanted green fluorescent protein+ bone marrow cells into adipose tissue. *Stem Cells*. 2008;26(2):330–8. Epub 2007/11/03.
121. Sera Y, LaRue AC, Moussa O, Mehrotra M, Duncan JD, Williams CR, et al. Hematopoietic stem cell origin of adipocytes. *Exp Hematol*. 2009;37(9):1108–20. Epub 2009/07/07.
122. Koh YJ, Kang S, Lee HJ, Choi TS, Lee HS, Cho CH, et al. Bone marrow-derived circulating progenitor cells fail to transdifferentiate into adipocytes in adult adipose tissues in mice. *J Clin Invest*. 2007;117(12):3684–95.
123. Majka SM, Fox KE, Psilas JC, Helm KM, Childs CR, Acosta AS, et al. De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific. *Proc Natl Acad Sci U S A*. 2010;107(33):14781–6. Epub 2010/08/04.
124. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. *Proc Nutr Soc*. 2009;68(4):370–7. Epub 2009/08/25.
125. Marques BG, Hausman DB, Martin RJ. Association of fat cell size and paracrine growth factors in development of hyperplastic obesity. *Am J Physiol*. 1998;275(6 Pt 2):R1898–908.

126. Maumus M, Sengenès C, Decaunes P, Zakaroff-Girard A, Bourlier V, Lafontan M, et al. Evidence of in situ proliferation of adult adipose tissue-derived progenitor cells: influence of fat mass microenvironment and growth. *J Clin Endocrinol Metab.* 2008;93(10):4098–106.
127. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. *Diabetes.* 2002;51(6):1699–707.
128. Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. *Endocrinology.* 2007;148(2):868–77.
129. Bourlier V, Zakaroff-Girard A, Miranville A, De Barros S, Maumus M, Sengenès C, et al. Remodeling phenotype of human subcutaneous adipose tissue macrophages. *Circulation.* 2008;117(6):806–15. Epub 2008/01/30.
130. Keophiphath M, Achard V, Henegar C, Rouault C, Clement K, Lacasa D. Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. *Mol Endocrinol.* 2009;23(1):11–24. Epub 2008/10/24.
131. Molgat AS, Gagnon A, Foster C, Sorisky A. The activation state of macrophages alters their ability to suppress preadipocyte apoptosis. *J Endocrinol.* 2012;214(1):21–9. Epub 2012/05/05.
132. Ellis JR, McDonald RB, Stern JS. A diet high in fat stimulates adipocyte proliferation in older (22 month) rats. *Exp Gerontol.* 1990;25(2):141–8. Epub 1990/01/01.
133. Roldan M, Macias-Gonzalez M, Garcia R, Tinahones FJ, Martin M. Obesity short-circuits stemness gene network in human adipose multipotent stem cells. *FASEB J.* 2011;25(12):4111–26. Epub 2011/08/19.
134. Tang W, Zeve D, Seo J, Jo AY, Graff JM. Thiazolidinediones regulate adipose lineage dynamics. *Cell Metab.* 2011;14(1):116–22. Epub 2011/07/05.
135. Kissebah AH, Vydellingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, et al. Relation of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab.* 1982;54(2):254–60.
136. McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. *J Clin Endocrinol Metab.* 2011;96(11):E1756–60. Epub 2011/08/26.
137. Kovacova Z, Tencerova M, Roussel B, Wedellova Z, Rossmeislova L, Langin D, et al. The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue. *Int J Obes (Lond).* 2012;36(10):1360–5. Epub 2011/12/07.
138. Amati F, Pennant M, Azuma K, Dube JJ, Toledo FG, Rossi AP, et al. Lower thigh subcutaneous and higher visceral abdominal adipose tissue content both contribute to insulin resistance. *Obesity (Silver Spring).* 2012;20(5):1115–7. Epub 2012/01/21.
139. Michaud A, Drolet R, Noel S, Paris G, Tchernof A. Visceral fat accumulation is an indicator of adipose tissue macrophage infiltration in women. *Metabolism.* 2012;61(5):689–98. Epub 2011/12/14.
140. Guo Z, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. *Diabetes.* 1999;48(8):1586–92.
141. Tordjman J, Divoux A, Prifti E, Poitou C, Pelloux V, Hugol D, et al. Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. *J Hepatol.* 2012;56(5):1152–8. Epub 2012/01/17.
142. Pinnick KE, Neville MJ, Fielding BA, Frayn KN, Karpe F, Hodson L. Gluteofemoral adipose tissue plays a major role in production of the lipokine palmitoleate in humans. *Diabetes.* 2012;61(6):1399–403. Epub 2012/04/12.
143. Snijder MB, Dekker JM, Visser M, Yudkin JS, Stehouwer CD, Bouter LM, et al. Larger thigh and hip circumferences are associated with better glucose tolerance: the Hoorn study. *Obes Res.* 2003;11(1):104–11.
144. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Yudkin JS, et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. *Diabetes Care.* 2004;27(2):372–7.
145. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. *Int J Obes (Lond).* 2010;34(6):949–59. Epub 2010/01/13.
146. Joe AW, Yi L, Even Y, Vogl AW, Rossi FM. Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. *Stem Cells.* 2009;27(10):2563–70. Epub 2009/08/07.
147. Tchkonja T, Lenburg M, Thomou T, Giorgadze N, Frampton G, Pirtskhalava T, et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. *Am J Physiol Endocrinol Metab.* 2007;292(1):E298–307.
148. Van Harmelen V, Rohrig K, Hauner H. Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. *Metabolism.* 2004;53(5):632–7.
149. Hauner H, Entenmann G. Regional variation of adipose differentiation in cultured stromal-vascular cells from the abdominal and femoral adipose tissue of obese women. *Int J Obes.* 1991;15(2):121–6.
150. Tchoukalova YD, Koutsari C, Votruba SB, Tchkonja T, Giorgadze N, Thomou T, et al. Sex- and Depot-Dependent Differences in Adipogenesis in Normal-Weight Humans. *Obesity (Silver Spring).* 2010;18(10):1875–80. Epub 2010/03/20.

151. Tchkonina T, Giorgadze N, Pirtskhalava T, Tchoukalova Y, Karagiannides I, Forse RA, et al. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. *Am J Physiol Regul Integr Comp Physiol*. 2002;282(5):R1286–96.
152. Miranville A, Heeschen C, Sengenès C, Curat CA, Busse R, Bouloumié A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. *Circulation*. 2004;110(3):349–55.
153. Macotela Y, Emanuelli B, Mori MA, Gesta S, Schulz TJ, Tseng YH, et al. Intrinsic differences in adipocyte precursor cells from different white fat depots. *Diabetes*. 2012;61(7):1691–9. Epub 2012/05/19.
154. Permana PA, Nair S, Lee YH, Luczy-Bachman G, Vozarova De Courten B, Tataranni PA. Subcutaneous abdominal preadipocyte differentiation in vitro inversely correlates with central obesity. *Am J Physiol Endocrinol Metab*. 2004;286(6):E958–62.
155. Cantile M, Procino A, D'Armiento M, Cindolo L, Cillo C. HOX gene network is involved in the transcriptional regulation of in vivo human adipogenesis. *J Cell Physiol*. 2003;194(2):225–36.
156. Vohl MC, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. *Obes Res*. 2004;12(8):1217–22.
157. Gesta S, Bluher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. *Proc Natl Acad Sci U S A*. 2006;103(17):6676–81.
158. Tchkonina T, Giorgadze N, Pirtskhalava T, Thomou T, DePonte M, Koo A, et al. Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. *Diabetes*. 2006;55(9):2571–8.
159. Cartwright MJ, Schlauch K, Lenburg ME, Tchkonina T, Pirtskhalava T, Cartwright A, et al. Aging, depot origin, and preadipocyte gene expression. *J Gerontol A Biol Sci Med Sci*. 2010;65(3):242–51. Epub 2010/01/29.
160. Yamamoto Y, Gesta S, Lee KY, Tran TT, Saadatirad P, Kahn CR. Adipose depots possess unique developmental gene signatures. *Obesity (Silver Spring)*. 2010;18(5):872–8. Epub 2010/01/30.
161. Monteiro MC, Sanyal M, Cleary ML, Sengenès C, Bouloumié A, Dani C, et al. PBX1: a novel stage-specific regulator of adipocyte development. *Stem Cells*. 2011;29(11):1837–48. Epub 2011/09/17.
162. Shi H, Clegg DJ. Sex differences in the regulation of body weight. *Physiol Behav*. 2009;97(2):199–204. Epub 2009/03/03.
163. Karastergiou K, Fried SK. Sex differences in human adipose tissues—the biology of pear shape. *Biol Sex Differ*. 2012;3(1):13. Epub 2012/06/02.
164. de Ridder CM, Bruning PF, Zonderland ML, Thijssen JH, Bonfrer JM, Blankenstein MA, et al. Body fat mass, body fat distribution, and plasma hormones in early puberty in females. *J Clin Endocrinol Metab*. 1990;70(4):888–93. Epub 1990/04/01.
165. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. *Lancet*. 1993;341(8850):938–41.
166. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. *J Clin Invest*. 1995;96(1):88–98.

Adipose Tissue and Adipokines in Health and Disease

Fantuzzi, G.; Braunschweig, C. (Eds.)

2014, XXVI, 372 p. 38 illus., 25 illus. in color., Hardcover

ISBN: 978-1-62703-769-3

A product of Humana Press